Donafenib intolerance in hepatocellular carcinoma: severe hand–foot skin reaction and successful switch to lenvatinib – a case report and literature review

BackgroundDonafenib is an approved multikinase inhibitor for hepatocellular carcinoma (HCC). However, cutaneous toxicity—particularly hand–foot skin reaction (HFSR)—may necessitate treatment interruption and compromise therapeutic continuity.Case presentationA 58-year-old man with HCC on a cirrhotic...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ying Chen, Linglin Fu, Ping Song, Yinuo Tan, Yuqi Jin
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-12-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	donafenib hepatocellular carcinoma hand–foot skin reaction acral toxicity lenvatinib tyrosine kinase inhibitor
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1728098/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!